FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents a C5 antibody or a fragment thereof, wherein the antibody or fragment thereof specifically binds to C5 and inhibits complement-dependent haemolysis, but does not block the formation of C5a, wherein the antibody comprises a first amino acid sequence and a second amino acid sequence. Invention also relates to a method of treating or reducing cases of eye disease associated with complement activation. Method involves administering an effective amount of the antibody to a patient and thereby treating or reducing the incidence of the disease.
EFFECT: higher efficiency of treatment.
17 cl, 14 dwg, 5 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO COMPLEMENT Bb FACTOR | 2015 |
|
RU2673036C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF DEGOS DISEASE | 2011 |
|
RU2570390C2 |
| C5 ANTIBODIES AND METHODS FOR USING THEM | 2016 |
|
RU2742606C2 |
| HUMANIZED ANTIBODY TO CONFORMATIONAL C3 EPITOPE CONSTITUENT OF HUMAN COMPLEMENT, DNA SEQUENCE (VERSIONS), EXPRESSION VECTOR CONTAINING DNA SEQUENCE (VERSIONS), AND OVARIAN CELLS' STRAIN OF CHINESE HAMSTER CHO-HUMC34-PRODUCER OF THIS HUMANIZED ANTIBODY | 2016 |
|
RU2630647C1 |
| DOSES AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) | 2020 |
|
RU2822664C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| THERAPEUTIC ANTIBODIES | 2012 |
|
RU2616881C2 |
| PHARMACEUTICAL COMPOSITION FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2018 |
|
RU2786053C2 |
| MODULATION OF COMPLEMENT ACTIVITY | 2015 |
|
RU2670988C2 |
